CL2013001054A1 - Compounds derived from cyanopyrazoles, modulators of the activity of the gpr119 receptor coupled to the g protein; pharmaceutical composition; and method to treat a disease, condition, or metabolic disorder selected from hyperlipidemia, type I diabetes, type II diabetes mellitus, type I idiopathic diabetes, among others. - Google Patents

Compounds derived from cyanopyrazoles, modulators of the activity of the gpr119 receptor coupled to the g protein; pharmaceutical composition; and method to treat a disease, condition, or metabolic disorder selected from hyperlipidemia, type I diabetes, type II diabetes mellitus, type I idiopathic diabetes, among others.

Info

Publication number: CL2013001054A1
Authority: CL; Chile
Prior art keywords: type; diabetes; cyanopyrazoles; hyperlipidemia; modulators
Prior art date: 2010-11-23

Application number

CL2013001054A

Other languages

Spanish (es)

Inventor

Vincent Mascitti

Kim Francis Mcclure

Michael John Munchhof

Ralph Pelton Robinson Jr

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-23

Filing date

2013-04-16

Publication date

2013-09-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45418722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013001054(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-04-16 Application filed by Pfizer filed Critical Pfizer

2013-09-27 Publication of CL2013001054A1 publication Critical patent/CL2013001054A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2013001054A 2010-11-23 2013-04-16 Compounds derived from cyanopyrazoles, modulators of the activity of the gpr119 receptor coupled to the g protein; pharmaceutical composition; and method to treat a disease, condition, or metabolic disorder selected from hyperlipidemia, type I diabetes, type II diabetes mellitus, type I idiopathic diabetes, among others. CL2013001054A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41644110P	2010-11-23	2010-11-23

Publications (1)

Publication Number	Publication Date
CL2013001054A1 true CL2013001054A1 (en)	2013-09-27

Family

ID=45418722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013001054A CL2013001054A1 (en)	2010-11-23	2013-04-16	Compounds derived from cyanopyrazoles, modulators of the activity of the gpr119 receptor coupled to the g protein; pharmaceutical composition; and method to treat a disease, condition, or metabolic disorder selected from hyperlipidemia, type I diabetes, type II diabetes mellitus, type I idiopathic diabetes, among others.

Country Status (27)

Country	Link
EP (1)	EP2643310A1 (en)
JP (1)	JP2013543885A (en)
KR (1)	KR20130083915A (en)
CN (1)	CN103298801A (en)
AP (1)	AP2013006809A0 (en)
AR (1)	AR088121A1 (en)
AU (1)	AU2011333427A1 (en)
BR (1)	BR112013011865A2 (en)
CA (1)	CA2814231A1 (en)
CL (1)	CL2013001054A1 (en)
CO (1)	CO6801716A2 (en)
CR (1)	CR20130139A (en)
CU (1)	CU20130059A7 (en)
DO (1)	DOP2013000102A (en)
EA (1)	EA201370118A1 (en)
EC (1)	ECSP13012630A (en)
GT (1)	GT201300135A (en)
MA (1)	MA34805B1 (en)
MX (1)	MX2013004083A (en)
NI (1)	NI201300044A (en)
PE (1)	PE20140409A1 (en)
PH (1)	PH12013500677A1 (en)
SG (1)	SG189830A1 (en)
TW (1)	TWI433843B (en)
UY (1)	UY33742A (en)
WO (1)	WO2012069948A1 (en)
ZA (1)	ZA201302362B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN103958495B (en)	2011-06-09	2018-06-22	理森制药股份公司	The compound of conditioning agent as GPR-119
JP2015522080A (en)	2012-07-11	2015-08-03	エルセリクスセラピューティクスインコーポレイテッド	Compositions for reducing cardiovascular metabolic risk comprising statins, biguanides, and additional agents
JP2017119628A (en) *	2014-05-09	2017-07-06	日産化学工業株式会社	Substituted azole compound and therapeutic agent for diabetes
CN104592120A (en) *	2015-02-13	2015-05-06	佛山市赛维斯医药科技有限公司	Cyclopropyl hydrazide and methoxybenzene-containing GPR119 agonist as well as preparation method and application thereof
CN104892517A (en) *	2015-02-13	2015-09-09	佛山市赛维斯医药科技有限公司	Hydrazine compound, method for preparing same and application of hydrazine compound
CN104610151A (en) *	2015-02-13	2015-05-13	佛山市赛维斯医药科技有限公司	Compound containing hydrazide and alkoxy benzene structures as well as preparation method and application thereof
EP3416959B1 (en)	2016-02-18	2021-05-12	Syngenta Participations AG	Pesticidally active pyrazole derivatives
CN106631992B (en) *	2017-01-05	2019-01-18	桑迪亚医药技术（上海）有限责任公司	A kind of synthetic method of 4- oxygen -3,4- dihydro -2H- pyridine -1- t-butyl formate
CN115925702B (en) *	2022-12-14	2025-04-25	江西凌富生物科技有限公司	A purification method of imidazo[4,5-C]pyridine derivatives and imidazo[4,5-C]pyridine derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009014910A2 (en) *	2007-07-19	2009-01-29	Metabolex, Inc.	N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
US20090270404A1 (en) *	2008-03-31	2009-10-29	Metabolex, Inc.	Oxymethylene aryl compounds and uses thereof
CN102459222B (en) *	2009-06-05	2014-06-04	辉瑞大药厂	L-(piperidin-4-yl)-pyrazole derivatives as modulators of GPR119

2011
- 2011-11-09 AP AP2013006809A patent/AP2013006809A0/en unknown
- 2011-11-09 PE PE2013001058A patent/PE20140409A1/en not_active Application Discontinuation
- 2011-11-09 MA MA35928A patent/MA34805B1/en unknown
- 2011-11-09 AU AU2011333427A patent/AU2011333427A1/en not_active Abandoned
- 2011-11-09 WO PCT/IB2011/054996 patent/WO2012069948A1/en not_active Ceased
- 2011-11-09 CN CN2011800550665A patent/CN103298801A/en active Pending
- 2011-11-09 PH PH1/2013/500677A patent/PH12013500677A1/en unknown
- 2011-11-09 EP EP11802149.2A patent/EP2643310A1/en not_active Withdrawn
- 2011-11-09 CA CA2814231A patent/CA2814231A1/en not_active Abandoned
- 2011-11-09 EA EA201370118A patent/EA201370118A1/en unknown
- 2011-11-09 JP JP2013540458A patent/JP2013543885A/en active Pending
- 2011-11-09 KR KR1020137013064A patent/KR20130083915A/en not_active Ceased
- 2011-11-09 SG SG2013023189A patent/SG189830A1/en unknown
- 2011-11-09 MX MX2013004083A patent/MX2013004083A/en unknown
- 2011-11-09 BR BR112013011865A patent/BR112013011865A2/en not_active IP Right Cessation
- 2011-11-21 UY UY0001033742A patent/UY33742A/en unknown
- 2011-11-22 AR ARP110104351A patent/AR088121A1/en not_active Application Discontinuation
- 2011-11-22 TW TW100142804A patent/TWI433843B/en not_active IP Right Cessation
2013
- 2013-03-22 CR CR20130139A patent/CR20130139A/en unknown
- 2013-04-02 ZA ZA2013/02362A patent/ZA201302362B/en unknown
- 2013-04-16 CL CL2013001054A patent/CL2013001054A1/en unknown
- 2013-04-23 CU CU2013000059A patent/CU20130059A7/en unknown
- 2013-05-09 DO DO2013000102A patent/DOP2013000102A/en unknown
- 2013-05-13 NI NI201300044A patent/NI201300044A/en unknown
- 2013-05-20 EC ECSP13012630 patent/ECSP13012630A/en unknown
- 2013-05-21 GT GT201300135A patent/GT201300135A/en unknown
- 2013-05-23 CO CO13127143A patent/CO6801716A2/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20130083915A (en)	2013-07-23
CR20130139A (en)	2013-06-28
UY33742A (en)	2012-06-29
TW201300373A (en)	2013-01-01
GT201300135A (en)	2015-02-19
CO6801716A2 (en)	2013-11-29
BR112013011865A2 (en)	2016-08-23
AU2011333427A1 (en)	2013-04-11
TWI433843B (en)	2014-04-11
JP2013543885A (en)	2013-12-09
MA34805B1 (en)	2014-01-02
CA2814231A1 (en)	2012-05-31
SG189830A1 (en)	2013-06-28
EP2643310A1 (en)	2013-10-02
PH12013500677A1 (en)	2013-05-06
ECSP13012630A (en)	2013-07-31
WO2012069948A1 (en)	2012-05-31
CU20130059A7 (en)	2013-06-28
NI201300044A (en)	2013-08-01
PE20140409A1 (en)	2014-03-23
CN103298801A (en)	2013-09-11
DOP2013000102A (en)	2013-07-15
AR088121A1 (en)	2014-05-14
MX2013004083A (en)	2013-06-13
ZA201302362B (en)	2014-06-25
AP2013006809A0 (en)	2013-04-30
EA201370118A1 (en)	2013-12-30

Similar Documents

Publication	Publication Date	Title
CL2013001054A1 (en)	2013-09-27	Compounds derived from cyanopyrazoles, modulators of the activity of the gpr119 receptor coupled to the g protein; pharmaceutical composition; and method to treat a disease, condition, or metabolic disorder selected from hyperlipidemia, type I diabetes, type II diabetes mellitus, type I idiopathic diabetes, among others.
CL2008002110A1 (en)	2008-10-24	PROCEDURE FOR THE MODULATION OF THE RECEPTOR COUPLED TO PROTEIN G GPR119 TO ADMINISTER A COMPOUND DERIVED FROM PIRIDINONE AND OPTIONALLY AN OPTIONAL THERAPEUTIC AGENT TO TREAT MELLITUS DIABETES.
EA201001329A1 (en)	2011-04-29	COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
EA201001332A1 (en)	2011-04-29	COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
CL2013000787A1 (en)	2013-09-23	Compounds derived from substituted fused benzamide, bradykinin receptor modulators; Pharmaceutical composition, useful in the treatment of acute, visceral, neuropathic pain, skin inflammation, among others.
CL2013000716A1 (en)	2013-08-09	A prodrug or a salt thereof comprising an exendin-conjugate conjugate; preparation procedure of said prodrug; intermediary compounds; pharmaceutical composition that includes it, useful to improve glycemic control in patients with type 2 diabetes.
SMT201600216B (en)	2016-08-31	OCTAIDROPIRROL [3,4.C] PIRROLS DISTRIBUTED AS MODULATORS OF OREXINA RECEPTOR
EA201001330A1 (en)	2011-04-29	COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
CL2010001496A1 (en)	2011-08-05	Compounds derived from (pyridin- or pyrimidin-) piperidine, gpr119 agonists; pharmaceutical composition; and its use for the treatment of type I diabetes, type II diabetes and related diseases such as metabolic syndrome, dyslipidemia and insulin resistance.
CL2013003598A1 (en)	2014-07-11	Compounds derived from benzooxazepinone, sodium channel modulators; pharmaceutical composition comprising them; and its use in the treatment of selected diseases of arrhythmias, heart failure, angina, myocardial infarction, diabetes, among others
CL2013000714A1 (en)	2013-10-11	Compounds derived from piperidinyl substituted lactams, modulators of gpr119; Preparation process; pharmaceutical composition that includes them; treatment method; and use of the compound to treat diseases such as type 2 diabetes, metabolic syndrome, dyslipidemia, hypertension and schizophrenia, among others.
CL2008000198A1 (en)	2008-05-30	COMPOUNDS DERIVED FROM AZACICLOALCANOS, INHIBITORS FROM ESTEAROIL-COENZIMA TO DELTA-9; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF SICK DISEASES AS TYPE 2 DIABETES, LIPID DISORDER, OBESITY AND ATEROSCLEROSIS.
UA108912C2 (en)	2015-06-25	A protein that binds TNF-α
BRPI1008971A2 (en)	2016-03-15	methods for preparing a conditionally active biological protein, and a conditionally active biological response modifier, conditionally active biological protein, and pharmaceutical composition
CL2008000690A1 (en)	2008-09-12	COMPOUNDS DERIVED FROM INDOL-3-PROPIONIC ACID; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA, HYPERTENSION; AMONG OTHER.
CL2007002348A1 (en)	2008-08-08	HETEROCICLICAL COMPOUNDS, MODULATORS OF THE ACTIVITY OF ESTEAROIL-COA-DESATURASA; PHARMACEUTICAL COMPOSITION, USEFUL FOR THE TREATMENT OF DISEASES SUCH AS DIABETES, DISLIPIDEMIAS, OBESITY, ANOREXIA AND ACNE.
BRPI1012116A2 (en)	2016-03-15	pharmaceutical composition for the treatment of heart disease
EP2578209A4 (en)	2014-10-29	NANOPARTICULAR COMPOSITION CONTAINING ANTIBIOTICS FOR INTRAMAMMARY ADMINISTRATION, FOR ANIMAL USE
BRPI0915382A2 (en)	2017-06-27	compound, pharmaceutical composition, and method for treating a disease or disorder.
BR112012004333A2 (en)	2015-09-08	compound, pharmaceutical composition, and method for treating or preventing a disease or disorder.
CL2013002414A1 (en)	2014-01-24	Compounds derived from cyclic azabenzimidazole, activators of amp-activated protein kinase; pharmaceutical composition that includes them; and its use for treatment or disease such as type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and hypertension.
EA201290964A1 (en)	2013-05-30	Peptide Conjugates of GLP-1 Receptor Agonists and Their Use
CL2013002053A1 (en)	2013-11-29	Heterocyclic derivative compounds, glucagon receptor antagonists; pharmaceutical composition that includes it and its use in the treatment of diabetes and metabolic diseases. pct
BRPI1008145A2 (en)	2016-03-15	bispecific antigen binding protein, method for preparing a bispecific antigen binding protein, host cell, pharmaceutical composition, use of the bispecific antigen binding protein and method for treating a patient.
BR112013031712A2 (en)	2017-07-04	compound, pharmaceutical composition, methods for preparing a compound and for treating a disorder or disease.